Cancer Research

Will Clinical Success Drive Regeneron to New Heights?
Research & Development Will Clinical Success Drive Regeneron to New Heights?

A massive capital infusion from Sixth Street Partners, which added over 846,000 shares, signals a strong bet on the next phase of Regeneron’s medical pipeline. This institutional confidence arrives as the biotechnology giant demonstrates remarkable clinical prowess, particularly with its latest

Can Fagopyrine From Buckwheat Target AKT1 to Fight Cancer?
Tech & Innovation Can Fagopyrine From Buckwheat Target AKT1 to Fight Cancer?

The inherent phototoxicity and potential carcinogenicity of natural fagopyrine require chemical engineers to modify the molecule before it can be considered for human trials. This reality underscores the dual nature of natural compounds: while they offer a rich library of chemical structures

Can Metabolism Boost the Immune Fight Against Colon Cancer?
Research & Development Can Metabolism Boost the Immune Fight Against Colon Cancer?

Enhancing the fat-burning capabilities of CAR T cells allows these engineered immune units to penetrate and kill solid tumor cells more effectively. This development arrives as colorectal cancer has transitioned into the leading cause of cancer-related mortality for adults under the age of 50. The

How Will PrimeStack Revolutionize Large-Scale Gene Editing?
Research & Development How Will PrimeStack Revolutionize Large-Scale Gene Editing?

Using junction-specific PCR analyses, researchers confirmed that PrimeStack can achieve success rates that are significantly higher than traditional targeted insertion methods. This breakthrough addresses a challenge that has frustrated plant scientists for decades: the extreme difficulty of

Nano-Diosmin Shows Dual Promise in Cancer and Kidney Care
Research & Development Nano-Diosmin Shows Dual Promise in Cancer and Kidney Care

While further human clinical trials are necessary, these preclinical findings suggest that nano-encapsulated diosmin could eventually provide a vital safety net for the kidneys of cancer patients. This assertion follows a significant breakthrough led by researcher Ahmad Najem Alshammari at Northern

Ohio State Trial Advances Trispecific CAR T-Cell Therapy
Research & Development Ohio State Trial Advances Trispecific CAR T-Cell Therapy

Standard immunotherapy often fails when cancer cells stop expressing a single target protein, a biological loophole that the new trispecific design aims to close by targeting CD19, CD20, and CD22. This experimental breakthrough, emerging from a phase I clinical trial at The Ohio State University

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later